⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15140923 | 0.92 | ALDH1A1 (0.30) | — | |
| SCHEMBL28191223 | 0.89 | — | — | |
| SCHEMBL12493615 | 0.84 | — | — | |
| Boric Acid SCHEMBL28211127 | 0.80 | — | — | |
| Boric Acid SCHEMBL28552959 | 0.80 | — | — | |
| Boric Acid SCHEMBL3103209 | 0.75 | — | — | |
| SCHEMBL14520947 | 0.73 | — | — | |
| SCHEMBL362863 | 0.72 | — | — | |
| Boric Acid SCHEMBL28399883 | 0.71 | ANPEP (0.38) | — | |
| Boric Acid SCHEMBL362365 | 0.69 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149789-A1 | PROCESS FOR THE PREPARATION OF SPARSENTAN | PROCOS S.P.A. (IT) | 2025-07-17 | — | — | WO | claimed |
| CN-115536681-B | Method for selectively synthesizing p-pinacol boron ester substituted anisole compound | 广西科学院 | 2024-12-24 | — | — | CN | claimed |
| CN-117143108-B | 8-bromo-2-methylbenzofuran [2,3-b ] pyridine and synthetic method | 蒲城欧得新材料有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117143108-A | 8-bromo-2-methylbenzofuran [2,3-b ] pyridine and synthetic method | 蒲城欧得新材料有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-116023392-A | Synthesis and application of benzo [1,2-c:4,5-c' -bis ([ 1,2,5] thiadiazole) dye | 南京信息工程大学 | 2023-04-28 | — | — | CN | claimed |
| CN-114478204-A | Preparation method of dapagliflozin impurity | 江苏万邦生化医药集团有限责任公司 | 2022-05-13 | — | — | CN | claimed |
| EP-4745116-A1 | PREPARATION METHOD FOR KRAS G12D INTERMEDIATE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260136824-A1 | LIGHT-EMITTING MATERIAL WITH A POLYCYCLIC LIGAND | BEIJING SUMMER SPROUT TECH CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| CN-121873105-A | 2-Isopropyl-5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) thiazole and synthetic method and application thereof | 凯美克(上海)医药科技有限公司 | 2026-04-17 | — | — | CN | disclosed |
| US-20260059935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-26 | — | — | US | disclosed |
| US-12557543-B2 | Light-emitting material with a polycyclic ligand | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| EP-2217591-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090286995-A1 | METHOD FOR THE PRODUCTION OF BORONIC ACIDS CARRYING CYANOALKYL, CARBOXYL AND AMINOCARBONYL GROUPS AND THEIR DERIVATIVES | ARCHIMICA GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009061271-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |